

## Curriculum Vitae

### Informazioni personali

Cognome/Nome	<b>Tesei Anna</b>
Codice Fiscale	
Telefono	
Fax	
E-mail	anna.tesei@irst.emr.it
Cittadinanza	italiana
Data di nascita	
Sesso	
Stato familiare	
Figli	

### Occupazione

**Responsabile Struttura Semplice Drug Discovery Unit e Radiobiologia - Struttura Complessa Laboratorio di Bioscienze -Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l. IRCCS, Via P. Maroncelli, 40 – 47014 Meldola (FC)**

Principali attività e responsabilità	Ricerca Traslazionale
Nome e indirizzo del datore di lavoro	Istituto scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), via Pero Maroncelli, 34/36, 47014, Meldola (FC), Italia
Tipo di attività o settore	<p>La Dr.ssa Tesei da febbraio 2007 è assunta presso IRCCS-Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (I.R.S.T), Meldola (FC) in qualità di Dirigente Biologo e Referente Responsabile del Laboratorio di Farmacologia Preclinica. Dal 2011 risulta anche referente del Laboratorio di Radiobiologia e in tal veste coordina le attività di ricerca preclinica della U.O. di Radioterapia. Dal 01/07/2016 a tutt'oggi risulta Responsabile della Struttura Semplice Drug Discovery Unit e Radiobiologia.</p> <p>Ha oltre 15 anni di esperienza di ricerca nel campo della farmacologia preclinica (studio dei meccanismi di azione dei farmaci antitumorali, saggi in vitro di chemio sensibilità e tossicità, studio dell'efficacia di nuove combinazioni di farmaci). Il team da lei coordinato si occupa in particolare dello studio dei meccanismi biomolecolari coinvolti nella radioresistenza e radiosensibilità delle cellule tumorali e nella caratterizzazione dei meccanismi molecolari coinvolti nella crescita tumorale, nelle alterazioni del ciclo cellulare e dei differenti tipi di danno cellulare indotti da trattamenti chimici e fisici. Da sempre la dr.ssa Tesei si occupa della messa a punto di nuovi modelli sperimentali in vitro, in particolare dell'ottenimento di colture cellulari tumorali primarie e di colture cellulari tridimensionali su cui testare farmaci e terapie radianti. Si occupa inoltre di isolamento di cellule staminali tumorali a partire da prelievi biotici ottenuti da pazienti affetti da tumore, della loro caratterizzazione biomolecolare e dei meccanismi volti al mantenimento della staminalità e del <i>self-renewal</i>. Attualmente si sta occupando della caratterizzazione del microambiente tumorale e in particolare della nicchia metastatica cerebrale.</p>

### Attività editoriale

Reviewer per Scientific Reports, Clinical Cancer Research, Computer Methods and Programs in Biomedicine, Cellular Physiology, British Journal of Pharmacology, Advanced Biosystems and other journals.

Review Editor per Frontiers in Endocrinology and Frontiers in Oncology

## Istruzione e formazione

- Marzo 1993: Laurea in Scienze Biologiche Vecchio Ordinamento (quadriennale) con voto 110/110 presso l'Università degli Studi di Bologna.
- Giugno 1994: Iscrizione all'Albo dell'Ordine Nazionale dei Biologi.
- Novembre 1998: Specializzazione in Biochimica e Chimica Clinica (quadriennale) con voto 50/50 presso l'Università degli Studi di Parma.
- Aprile 2006: Dottorato di Ricerca in Farmacologia e Tossicologia (quadriennale) presso l'Università degli Studi di Bologna.

## Esperienza professionale

- 1993-1994: tirocinio post-lauream obbligatorio per iscrizione all'Albo Professionale presso il Laboratorio Analisi dell'Ospedale "M.Bufalini", Cesena
- 1995-1997: incarichi di collaborazione coordinata e continuativa annuali per lo studio "Molecular Epidemiology on the effects of dioxin exposure in the Seveso Region" coordinato dal Professor Pier Alberto Bertazzi del "Centro Studi Epoca" di Milano svolto presso il Laboratorio Analisi dell'Ospedale "M.Bufalini", Cesena
- 1998: incarico di collaborazione coordinata e continuativa per lo studio "Molecular Epidemiology of Cutaneous Malignant Melanoma" presso il Dipartimento di Dermatologia dell'Ospedale "M.Bufalini" di Cesena, in collaborazione con il National Cancer Institute of Bethesda, MD, USA
- 1998 -2006: Incarichi libero professionali annuali conferiti dall'Istituto Oncologico Romagnolo (1998-2002) e tramite concorso dall'Azienda USL di Forlì (2003-2006), per attività di ricerca nel campo della farmacologia preclinica svolta presso il Dipartimento di Oncologia dell'Ospedale "G.B. Morgagni-L.Pierantoni", Forlì
- Dal 2007: Assunzione a tempo indeterminato come Dirigente Biologo in qualità di referente del settore della Farmacologia Preclinica, presso l'UO Laboratorio Biologico dell'Istituto Scientifico Romagnolo per lo studio e la Cura dei Tumori (IRST), Meldola-Forlì
- Dal 2011: Ricercatore Associato presso l'Istituto CNR-ISOF di Bologna
- Dal 07.2016: Responsabile di Struttura Semplice "Drug Discovery Unit e Radiobiologia"

## Brevetti

- US 8741951 B2. NON-STEROIDAL COMPOUNDS FOR ANDROGEN RECEPTOR MODULATION. Inventors: Greta Varchi,; Andrea Guerrini; Anna Tesei; Giovanni Brigliadori.
- US 8859599 B2. ANDROGEN RECEPTOR MODULATING COMPOUNDS, PREPARATION AND USES THEREOF. Inventors: Greta Varchi,; Andrea Guerrini; Anna Tesei; Giovanni Brigliadori

## Honors & Awards

2019: was Scientific Coordinator of a Research Unit taking part in the project entitled "CUBIBOX (Customized Biological/ Box): piattaforma di nuova generazione per testing in vitro" CUP E91F18000240007 -Bando POR Emilia-Romagna

2016 dr. Tesei was winner of Ministerial Health project -BANDO CONTO CAPITALE 2015\_ TITLE OF THE PROJECT PROPOSAL: Studio degli effetti delle radiazioni ionizzanti sulle cellule tumorali e del microambiente ipossico su modelli sperimentali in vitro e in vivo finalizzato all'ottimizzazione della terapia radiante- SCIENTIST IN CHARGE OF PROJECT PROPOSAL: Dr.ssa Anna Tesei ;

From 2006 to 2008 Dr. Tesei was Scientific Coordinator of a Research Unit taking part in a Ministerial Health project (Ministero della Salute Ricerca Finalizzata project - F.S.N. 2005 Conv.n.87, Project coordinator. Dr. A. Pinto) entitled "Terapie bersaglio-specifiche per il blocco delle interazioni tra cellule staminali mesenchimali e neoplastiche". Within the context of this project, she was involved in investigating the interplay between tumor and stroma cells.

In 2007 Dr. Tesei was head of a Research Unit in the Programma Integrato Oncologia project (P.I.O., Conv. N.RO Strategic 9/07 Ministerial Health project, Scientific Project coordinator, Prof. G. Zupi) entitled "Meccanismo d'azione ed efficacia di molecole biologiche e farmaci citotossici di ultima generazione e loro interazione". Within the context of this project, she focused on the antitumor activity of new anti-inflammatory agents releasing NO- molecules (NO-NSAIDs).

## Capacità e competenze personali

Madrelingua **Italiano**

Altra(e) lingua(e) **Inglese**

Autovalutazione

Livello europeo (\*)

**Inglese**

Comprensione		Parlato		Scritto
Ascolto	Lettura	Interazione orale	Produzione orale	
Livello Intermedio	Livello Elevato	Livello Intermedio	Livello Intermedio	Livello Elevato

## PUBBLICAZIONI IN EXTENSO

- Pignatta S, Cortesi M, Arienti C, Zanoni M, Cocchi C, Sarnelli A, Arpa D, Piccinini F, **Tesei A**. Effects of radiotherapy and short-term starvation combination on metastatic and non-tumor cell lines. DNA Repair 95 (2020) 1029-49.
- Listro R, Stotani S, Rossino G, Rui M, Malacrida A, Cavaletti G, Cortesi M, Arienti C, **Tesei A**, Rossi D, Giacomo MD, Miloso M, Collina S. Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents. Front Chem. 2020 Jun 30;8:495.
- Zanoni M, Cortesi M, Zamagni A, Arienti C, Pignatta S, Tesei A. Modeling neoplastic disease with spheroids and organoids. J Hematol Oncol. 2020 Jul 16;13(1):97.
- Zamagni A, Pasini A, Pirini F, Ravaioli S, Giordano E, **Tesei A**, Calistri D, Ulivi P, Fabbri F, Foca F, Delmonte A, Molinari C. CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells. Int J Oncol. 2020 Jun;56(6):1574-1584.
- Arienti C, Pignatta S, **Tesei A**. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Front Oncol. 2019 Nov 26;9:1308.
- Zamagni A, Cortesi M, Zanoni M, **Tesei A**. Non-nuclear AR Signaling in Prostate Cancer. Front. Chem., 26 September 2019 | <https://doi.org/10.3389/fchem.2019.00651>
- Zanoni M, Cortesi M, Zamagni A, **Tesei A**. The Role of Mesenchymal Stem Cells in Radiation-Induced Lung Fibrosis. Int J Mol Sci. 2019 Aug 8;20(16). pii: E3876. doi: 10.3390/ijms20163876. Review.
- Parisi E, Genestreti G, Sarnelli A, Ghigi G, Arpa D, Burgio MA, Gavelli G, Rossi A, Scarpi E, Monti M, **Tesei A**, Polico R, Romeo A. Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. Radiat Oncol. 2019 Jun 24;14(1):112.
- Tesei A**, Cortesi M, Pignatta S, Arienti C, Dondio GM, Bigogno C, Malacrida A, Miloso M, Meregalli C, Chiorazzi A, Carozzi V, Cavaletti G, Rui M, Marra A, Rossi D, Collina S. Anti-tumor Efficacy Assessment of the Sigma Receptor Pan Modulator RC-106. A Promising Therapeutic Tool for Pancreatic Cancer. Front Pharmacol. 2019 May 14;10:490.
- Zanoni M, Pignatta S, Arienti C, Bonafè M, **Tesei A**. Anticancer drug discovery using multicellular tumor spheroid models. Expert Opin Drug Discov. 2019 Mar;14(3):289-301.

11. Storci G, De Carolis S, Papi A, Bacalini MG, Gensous N, Marasco E, **Tesei A**, Fabbri F, Arienti C, Zanoni M, Sarnelli A, Santi S, Olivieri F, Mensà E, Latini S, Ferracin M, Salvioli S, Garagnani P, Franceschi C, Bonafè M. Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNaseH2 in cells from centenarians. *Cell Death Differ.* 2019 Jan 8.
12. Carragher N, Piccinini F, **Tesei A**, Trask Jr OJ, Bickle M, Horvath P. Concerns, challenges and promises of high-content analysis of 3D cellular models. *Nat Rev Drug Discov.* 2018 Aug;17(8):606.
13. **Tesei A**, Cortesi M, Zamagni A, Arienti C, Pignatta S, Zanoni M, Paolillo M, Curti M, Rui M, Rossi D, Collina S. Sigma receptors as endoplasmic reticulum stress "gatekeepers" and their modulators as emerging new weapons in the fight against cancer. *Frontiers in Pharmacology* 2018. *Front Pharmacol.* 2018 Jul 10;9:711.
14. Arienti C, Pignatta S, Zanoni M, Cortesi M, Zamagni A, Piccinini F, **Tesei A**. Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down. *J Vis Exp.* 2017 Dec 11;(130)
15. Piccinini F, **Tesei A**, Zanoni M, Bevilacqua A. ReViMS: Software tool for estimating the volumes of 3-D multicellular spheroids imaged using a light sheet fluorescence microscope. *Biotechniques.* 2017 Nov 1;63(5):227-229.
16. Parisi E, Romeo A, Sarnelli A, Ghigi G, Bellia SR, Neri E, Micheletti S, Dipalma B, Arpa D, Furini G, Burgio MA, Genestreti G, Gurioli C, Sanna S, Bovolato P, Rea F, Storme G, Scarpi E, Arienti C, **Tesei A**, Polico R. High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment. *Cancer Radiother.* 2017 Dec;21(8):766-773.
17. Carloni S, Gallerani G, **Tesei A**, Scarpi E, Verdecchia GM, Virzi S, Fabbri F, Arienti C. DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. *Onco Targets Ther.* 2017 Sep 20;10:4657-4664.
18. De Carolis S, Pellegrini A, Santini D, Ceccarelli C, Leo A, Alessandrini F, Arienti C, Pignatta S, **Tesei A**, Mantovani V, Zamagni C, Taffurelli M, Sansone P, Bonafè M, Cricca M. Liquid biopsy in the diagnosis of HPV DNA in breast lesions. *Future Microbiol.* 2017 Oct 4.
19. Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, **Tesei A**, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G. 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment. *J Med Chem.* 2017 Apr 13;60(7):3082-3093.
20. Collina S, Bignardi E, Rui M, Rossi D, Gaggeri R, Zamagni A, Cortesi M, **Tesei A**. Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016). *Expert Opin Ther Pat.* 2017 Jan 13:1-14.
21. Rui M, Rossi D, Marra A, Paolillo M, Schinelli S, Curti D, **Tesei A**, Cortesi M, Zamagni A, Laurini E, Pricl S, Schepmann D, Wünsch B, Urban E, Pace V, Collina S. Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents. *Eur J Med Chem.* 2016 Aug 31;124:649-665.
22. Piccinini F, **Tesei A**, Bevilacqua A. Single-image based methods used for non-invasive volume estimation of cancer spheroids: a practical assessing approach based on entry-level equipment. *Comput Methods Programs Biomed.* 2016 Oct;135:51-60
23. Arienti C, Zanoni M, Pignatta S, Del Rio A, Carloni S, Tebaldi M, Tedaldi G, **Tesei A**. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. *Oncotarget.* 2016 Feb 22. doi: 10.18632/oncotarget.7575.
24. Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, Bevilacqua A, **Tesei A**. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. *Scientific Reports,* 11January 2016.
25. De Carolis S, Bertoni S, Nati M, D'Anello L, Papi A, **Tesei A**, Cricca M, Bonafè M. Carbonic anhydrase 9 mRNA/microRNA34a interplay in hypoxic human mammospheres. *J Cell Physiol.* 2015 Nov 10. doi: 10.1002/jcp.25245.
26. Giustarini D, Galvagni F, **Tesei A**, Farolfi A, Zanoni M, Pignatta S, Milzani A, Marone IM, Dalle-Donne I, Nassini R, Rossi R. Glutathione, glutathione disulfide, and S-glutathionylated proteins in cell cultures. *Free Radic Biol Med.* 2015 Dec;89:972-81. doi: 10.1016/j.freeradbiomed.2015.10.41
27. Pasini A, Delmonte A, **Tesei A**, Calistri D, Giordano E. Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. *Drugs.* 2015 Oct;75(15):1757-71. doi: 10.1007/s40265-015-0461-3.
28. Pignatta S, Orienti O, Falconi M, Teti G, Arienti A, Medri L, Zanoni M, Carloni S, Zoli W, Amadori D, **Tesei A**. Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer. *Nanomedicine.* 2015 Feb;11(2):263-73. doi: 10.1016/j.nano.2014.10.004.

29. Piccinini F, **Tesei A**, Zoli W, Bevilacqua A. Cancer multicellular spheroids: volume assessment from a single 2D projection.. *Comput Methods Programs Biomed.* 2015 Feb;118(2):95-106. doi: 10.1016/j.cmpb.2014.12.003
30. Piccinini F, **Tesei A**, Paganelli G, Zoli W, Bevilacqua A. Improving reliability of live/dead cell counting through automated image mosaicing. *Computer Methods and Programs in Biomedicine*, DOI: 10.1016/j.cmpb.2014.09.004, September 2014.
31. Gibellini L, Pinti M, Boraldi F, Giorgio V, Bernardi P, Bartolomeo R, Nasi M, De Biasi S, Missiroli S, Carnevale G, Losi L, **Tesei A**, Pinton P, Quaglino D, Cossarizza A. Silencing of mitochondrial Lon protease deeply impairs mitochondrial proteome and function in colon cancer cells. *FASEB J.* 2014 Aug 25. pii: fj.14-255869.
32. Guerrini A, **Tesei A**, Ferroni C, Paganelli G, Zamagni A, Carloni S, Di Donato M, Castoria G, Leonetti C, Porru M, De Cesare M, Zaffaroni N, Beretta GL, Del Rio A, Varchi G. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides. *J Med Chem.* 2014 Sep 11;57(17):7263-79.
33. Durante S, Orienti I, Teti G, Salvatore V, Focaroli S, **Tesei A**, Pignatta S, Falconi M. Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model. *Oncotarget.* 2014 Jul 15;5(13):4811-20
34. Arienti C, Zoli W, Pignatta S, Carloni S, Paganelli G, Ulivi P, Romeo A, Menghi E, Sarnelli A, Medri L, Polico R, Silvestrini R, **Tesei A**. Efficacy of Different Sequences of Radio- and Chemotherapy in Experimental Models of Human Melanoma. *J Cell Physiol.* 2014 Mar 4. doi: 10.1002/jcp.24598.
35. Pignatta S, Arienti C, Zoli W, Di Donato M, Castoria G, Gabucci E, Casadio V, Falconi M, De Giorgi U, Silvestrini R, **Tesei A**. Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome. *Mol Cell Endocrinol.* 2014 Jan 25;382(1):314-24.
36. **Tesei A**, Sarnelli A, Arienti C, Menghi E, Medri L, Gabucci E, Pignatta S, Falconi M, Silvestrini R, Zoli W, D'Errico V, Romeo A, Parisi E, Polico R. In vitro irradiation system for radiobiological experiments. *Radiat Oncol.* 2013 Nov 1;8:257.
37. **Tesei A**, Leonetti C, Di Donato M, Gabucci E, Porru M, Varchi G, Guerrini A, Amadori D, Arienti C, Pignatta S, Paganelli G, Caraglia M, Castoria G, Zoli W. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models. *PLoS One.* 2013 May 8;8(5):e62657.
38. Pasini A, Paganelli G, **Tesei A**, Zoli W, Giordano E, Calistri D. Specific Biomarkers Are Associated with Docetaxel and Gemcitabine-Resistant NSCLC Cell Lines. *Transl Oncol.* 2012 Dec;5(6):461-8.
39. Arienti C, **Tesei A**, Verdecchia GM, Framarini M, Virzi S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W. Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. *Clin Colorectal Cancer.* 2013 Jun;12(2):122-7.
40. Arienti C, **Tesei A**, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R, Zoli W. SLUG silencing increases radiosensitivity of melanoma cells in vitro. *Cell Oncol (Dordr).* 2013 Apr;36(2):131-9.
41. Varchi G., Castoria G., Di Donato M., **Tesei A**., Brigliadori G., Bertucci C., Guerrini A. Non-steroidal androgen receptor ligands: versatile syntheses and biological data. *ACS Med. Chem. Lett.* 2012, 3, 454-458, 2012; dx.doi.org/10.1021/ml3000269
42. Ibrahim T, Mercatali L, Sacanna E, **Tesei A**, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int.* 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48.
43. Piccinini F, **Tesei A**, Zoli W, Bevilacqua A. Extended depth of focus in optical microscopy: assessment of exiting methods and a new proposal. *Microsc Res Tech.* 2012 Nov;75(11):1582-92. doi: 10.1002/jemt.22104..
44. Ulivi P, Romagnoli M, Chiadini E, Casoni GL, Capelli L, Gurioli C, Zoli W, Saragoni L, Dubini A, **Tesei A**, Amadori D, Poletti V. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. *Int J Oncol.* 2012 Jul;41(1):147-52. doi: 10.3892/ijo.2012.1432. Epub 2012 Apr 10.
45. **Tesei A**, Brigliadori G, Carloni S, Fabbri F, Ulivi P, Arienti C, Sparatore A, Del Soldato P, Pasini A, Amadori D, Silvestrini R, Zoli W. Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. *J Cell Physiol.* 2012 Oct;227(10):3389-96. doi: 10.1002/jcp.24039
46. Arienti C, **Tesei A**, Verdecchia GM, Framarini M, Virzi S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W. Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. *J Transl Med.* 2011 Jun 20;9:94.

47. Fabbri F, Zoli W, Carloni S, Ulivi P, Arienti C, Brigliadori G, Montanari M, **Tesei A**, Silvestrini R, Amadori D. Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus. *J Cell Physiol*. 2011 Nov;226(11):3035-42.
48. Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, **Tesei A**, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C. In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. *Curr Cancer Drug Targets*. 2010 Nov 1;10(6):600-10.
49. **Tesei A**, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. *J Cell Mol Med*. 2009 Dec 8.
50. Fabbri F, Brigliadori G, Carloni S, Ulivi P, **Tesei A**, Silvestrini R, Amadori D, Zoli W. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. *Prostate*. 2010 Feb 1;70(2):219-27.
51. Vannini I, Zoli W, Fabbri F, Ulivi P, **Tesei A**, Carloni S, Brigliadori G, Amadori D. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. *Anticancer Drugs*. 2009 Nov;20(10):918-25.
52. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, **Tesei A**, Vannini I, Silvestrini R, Zoli W. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. *J Cell Physiol*. 2009 Jul;220(1):214-2.
53. **Tesei A**, Zoli W, Arienti C, Storci G, Granato AM, Pasquinelli G, Valente S, Orrico C, Rosetti M, Vannini I, Dubini A, Dell'Amore D, Amadori D, Bonafè M. Isolation of stem/progenitor cells from normal lung tissue of adult humans. *Cell Prolif*. 2009 Jun;42(3):298-308.
54. Fabbri F, Amadori D, Carloni S, Brigliadori G, **Tesei A**, Ulivi P, Rosetti M, Vannini I, Arienti C, Zoli W, Silvestrini R. Mitotic Catastrophe and Apoptosis Induced by Docetaxel in Hormone-Refractory Prostate Cancer Cells. *Cell Physiol*. 2008 Nov;217(2):494-501.
55. Vannini I, Zoli W, **Tesei A**, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, Fabbri F, Ulivi P, Brigliadori G, Amadori D, Bonafè M. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. *Tumour Biol*. 2008;29(3):145-51. Epub 2008 Jul 9
56. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, **Tesei A**, Silvestrini R, Amadori D, Zoli W. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. *J Transl Med*. 2008 Aug 6;6:43.
57. **Tesei A**, Zoli W, Fabbri F, Leonetti C, Rosetti M, Bolla M, Amadori D, Silvestrini R. NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. *Nitric Oxide*. 2008 Apr 22.
58. Rosetti M, Frasnelli M, Fabbri F, Arienti C, Vannini I, **Tesei A**, Zoli W, Conti M. Pro-apoptotic activity of cyclopentenone in cancer cells. *Anticancer Res*. 2008 Jan-Feb;28(1A):315-20.
59. Arienti C, **Tesei A**, Ravaioli A, Ratta M, Carloni S, Mangianti S, Ulivi P, Nicoletti S, Amadori D, Zoli W. Activity of lipoplatin in tumor and in normal cells in vitro. *Anticancer Drugs*. 2008 Nov;19(10):983-90.
60. Passardi A, Maltoni R, Milandri C, Cecconetto L, Massa I, Zoli W, **Tesei A**, Fabbri F, Nanni O, Amadori D. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies. *Oncology*. 2007;72(1-2):118-24. Epub 2007 Nov 15.
61. **Tesei A**, Rosetti M, Ulivi P, Fabbri F, Medri L, Vannini I, Bolla M, Amadori D, Zoli W. Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. *J Transl Med*. 2007 Oct 30;5:52.
62. De Marco C, Zaffaroni N, Comijn E, **Tesei A**, Zoli W, Peters GJ. Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. *Int J Oncol*. 2007 Oct;31(4):907-13.
63. Rosetti M, Zoli W, **Tesei A**, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Granato A M, Amadori D, Silvestrini R. Iressa Strengthens the Cytotoxic Effect of Docetaxel in NSCLC Models that Harbor Specific Molecular Characteristics. *Cell Physiol*. 2007 Sep;212(3):710-6.
64. Vannini I, Bonafè M, **Tesei A**, Rosetti M, Fabbri F, Storci G, Ulivi P, Brigliadori G, Amadori D and Zoli W. Short interfering RNA directed against the Slug gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. *Cell Oncol*. 2007;29(4):279-87.
65. Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L, Fabbri F, Rosetti M, Ulivi P, Cecconetto L, Bolla M, **Tesei A**. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. *Mol Cancer Ther*. 2006 Apr;5(4):919-26.
66. Rosetti M, **Tesei A**, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Amadori D, Bolla M, Zoli W. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. *Apoptosis*, 2006 .

67. Ulivi P, Zoli W, Calistri D, Fabbri F, **Tesei A**, Rosetti M, Mengozzi M, Amadori D. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. *J Cell Physiol.* 2006 Mar;206(3):611-5.
68. Rosetti M, Frasnelli M, **Tesei A**, Zoli W, Conti M. Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. *J Exp Ther Oncol.* 2006;6(1):23-9.
69. **Tesei A**, Ulivi P, Fabbri F, Rosetti M, Leonetti C, Scarsella M, Zupi G, Amadori D, Bolla M, Zoli W. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. *J Transl Med.* 2005, Feb 3;3(1):7.
70. Ulivi P, Zoli W, Fabbri F, Brigliadori G, Ricotti L, **Tesei A**, Rosetti M, De Cesare M, Beretta GI, Corna E, Supino R, Zunino F. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. *Neoplasia*, 2005, 7:152-161.
71. Ibrahim T, Zoli W, Frassinetti GI, **Tesei A**, Colantonio I, Monti M, Amadori D. Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. *Lung Cancer*, 2005, 47:261-267.
72. Fabbri F, Brigliadori G, Ulivi P, **Tesei A**, Vannini I, Rosetti M, Bravaccini S, Amadori D, Bolla M, And Zoli W. Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. *Apoptosis*, 2005, Oct;10(5):1095-103.
73. Zoli W, Ulivi P, **Tesei A**, Fabbri F, Rosetti M, Maltoni R, Casadei Giunchi D, Ricotti L, Brigliadori G, Vannini I, Amadori D. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. *Breast Cancer Research*, 2005;7(5):R681-9.
74. Rosetti M, **Tesei A**, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Granato A, Amadori D, Zoli W. Modulation of drug cytotoxicity by iressa (ZD 1839) in pancreatic cancer cell lines. *Cancer Biol Ther*, 2005 Oct;4(10):1089-95.
75. Zoli W, Ricotti L, **Tesei A**, Ulivi P, Campani Ag, Fabbri F, Gunelli R, Frassinetti GI, Amadori D. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. *Clin Cancer Res*, 2004, 10: 1500-1507.
76. **Tesei A**, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W. NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. *Int J Oncol.* 2003, 22: 1297-1302.
77. Ricotti L, **Tesei A**, De Paola F, Milandri C, Amadori D, Frassinetti GI, Ulivi P, Zoli W. Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells. *J Chemother*, 2003, 15: 480-487.
78. Ricotti L, **Tesei A**, De Paola F, Ulivi P, Frassinetti GL, Milandri C, Amadori D, Zoli W. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. *Clin Cancer Res*, 2003, 9:900-905.
79. **Tesei A**, Ricotti L De Paola F, Amadori D, Frassinetti GL, Zoli W. In vitro schedule-dependent interactions between the multitargeted antifolate ly231514 and gemcitabine in human colon adenocarcinoma cell lines. *Clin. Cancer Res*, 2002, 8: 233-239.
80. Zoli W, Barzanti F, Dal Susino M, De Paola F, **Tesei A**, Ricotti L, Padovani F, Reno F, Amadori D. Flow-cytometric determination of tumor cells in lymphonodes. *Oncology*, 2002, 62:128-135.
81. Zoli W, Ricotti L, **Tesei A**, Barzanti F, Amadori D. *In vitro* preclinical models for a rational design of chemotherapy combinations in human tumors. *Crit Rev Oncol Hematol*, 2001, 37: 69-82.
82. Barzanti F, Zoli W, Susino M, Ricotti L, **Tesei A**, Papa S, Reno F, Amadori D. Simultaneous determination of apoptosis and surface antigen expression in tumor adherent cells. *J Biol Regul Homeost Agents*, 2001, 15: 359-365.
83. **Tesei A**, Ricotti L, De Paola F, Casini-Raggi C, Barzanti F, Frassinetti GL, Zoli W. Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study. *J Chemother*, 2000, 12: 421-430.
84. Ricotti L, Barzanti F, **Tesei A**, Amadori D, Gasperi-Campani A, Frassinetti GL, Zoli W. Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures. *Ann Oncol*, 2000, 11: 587-594.
85. Zoli W, Ricotti L, Dal Susino M, Barzanti F, Frassinetti GL, Folli S, **Tesei A**, Bacci F, Amadori D. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. *Br J Cancer*, 1999, 81(4): 609-615.

*Dichiaro di essere informato ai sensi e per gli effetti dell'art. 13 del D.lgs 196/2003, che il presente curriculum verrà allegato al programma dell'evento formativo e pubblicato nella banca dati presente nel sito <http://ecm.agenas.it>, e a tal fine presto il consenso al trattamento dei dati personali ivi contenuti*

Meldola 13-10-19

Anna Tesei